caa a22 4500 475833562 CHVBK 20180406123847.0 cr unu---uuuuu 170329e20000601xx s 000 0 eng 10.1023/A:1007820401377 doi (NATIONALLICENCE)springer-10.1023/A:1007820401377 Predicting Response to Chronic Antihypertensive Treatment with Fosinopril: The Role of Angiotensin-Converting Enzyme Gene Polymorphism [Elektronische Daten] [George Stavroulakis, Thomas Makris, Panagiota Krespi, Antonios Hatzizacharias, Argyri Gialeraki, George Anastasiadis, Philippos Triposkiadis, Michael Kyriakidis] Insertion (I)/deletion (D) polymorphism of the ACE gene has been reported to be involved in various cardiovascular diseases. We investigated prospectively whether the response to the ACE inhibitor fosinopril varied according to the ACE genotype in previously untreated Greek hypertensive patients. After a 4-week observation period, fosinopril was administered at a dose of 20 mg daily and blood pressure was measured weekly for 6 months. The study population consisted of 104 hypertensive patients (46 male, 58 female). There were no differences in age, gender, body mass index, and pretreatment blood pressure levels among patients with the DD, ID, and II genotypes (n = 42, 30, 32, respectively). The reduction in systolic blood pressure was significantly greater in patients carrying the DD compared to II or ID genotypes (5.6 ± 3.1 vs. 3.1 ± 1.1 or 3.6 ± 2.2, respectively; ANOVA, p < 0.05). The reduction in diastolic blood pressure was also significantly greater in DD hypertensives compared with II or ID (8.9 ± 6 vs. 5.5 ± 3.4 or 5.8 ± 4, respectively; ANOVA, p < 0.05). The age and BMI were not correlated with the changes in SBP or DBP that were observed after fosinopril administration. In conclusion, the ACE gene genotype was shown to influence the response to fosinopril in hypertensive patients. Kluwer Academic Publishers, 2000 fosinopril nationallicence genetics nationallicence antihypertensive response nationallicence Stavroulakis George Department of Cardiology, 2, Athens University Medical School, Athens, Greece aut Makris Thomas Department of Cardiology, 2, Athens University Medical School, Athens, Greece aut Krespi Panagiota Department of Cardiology, 2, Athens University Medical School, Athens, Greece aut Hatzizacharias Antonios Department of Cardiology, 2, Athens University Medical School, Athens, Greece aut Gialeraki Argyri Department of Cardiology, 2, Athens University Medical School, Athens, Greece aut Anastasiadis George Department of Cardiology, 2, Athens University Medical School, Athens, Greece aut Triposkiadis Philippos Department of Cardiology, 2, Athens University Medical School, Athens, Greece aut Kyriakidis Michael Department of Cardiology, 2, Athens University Medical School, Athens, Greece aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/4(2000-06-01), 427-432 0920-3206 14:4<427 2000 14 10557 https://doi.org/10.1023/A:1007820401377 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1007820401377 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Stavroulakis George Department of Cardiology, 2, Athens University Medical School, Athens, Greece aut NATIONALLICENCE 700 1- Makris Thomas Department of Cardiology, 2, Athens University Medical School, Athens, Greece aut NATIONALLICENCE 700 1- Krespi Panagiota Department of Cardiology, 2, Athens University Medical School, Athens, Greece aut NATIONALLICENCE 700 1- Hatzizacharias Antonios Department of Cardiology, 2, Athens University Medical School, Athens, Greece aut NATIONALLICENCE 700 1- Gialeraki Argyri Department of Cardiology, 2, Athens University Medical School, Athens, Greece aut NATIONALLICENCE 700 1- Anastasiadis George Department of Cardiology, 2, Athens University Medical School, Athens, Greece aut NATIONALLICENCE 700 1- Triposkiadis Philippos Department of Cardiology, 2, Athens University Medical School, Athens, Greece aut NATIONALLICENCE 700 1- Kyriakidis Michael Department of Cardiology, 2, Athens University Medical School, Athens, Greece aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/4(2000-06-01), 427-432 0920-3206 14:4<427 2000 14 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer